Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | EVP, GLOBAL SALES | August 01, 2024 | August 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date August 01, 2024 · Filed August 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Ending reported balance
After 2024-08-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-08-01 · Exercise / conversion · Acquired 15,476 · Balance 40,476 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Row 2 · 2024-08-01 · Sale · Disposed 15,476 · Balance 25,000 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.445 to $4.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2024-08-02 · Exercise / conversion · Acquired 17,857 · Balance 42,857 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Row 4 · 2024-08-02 · Sale · Disposed 17,857 · Balance 25,000 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.235 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2030-01-20 | Direct | 17,858 |
Reported balance
After 2024-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-01 · Exercise / conversion · Disposed 15,476 · Balance 17,858 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4: The option has fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2030-01-20 | Direct | 1 |
Reported balance
After 2024-08-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-02 · Exercise / conversion · Disposed 17,857 · Balance 1 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4: The option has fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.445 to $4.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.235 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The option has fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,467 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · derivative · entry 9 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 Underlying: Common Stock · 9,467 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 9,467 | $5.04 | $47,713.68 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · nonDerivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 9,467 | $0.98 | $9,306.06 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · nonDerivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,153 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · derivative · entry 8 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,935 Underlying: Common Stock · 9,153 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 9,153 | $5.07 | $46,405.71 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 9,153 | $0.98 | $8,997.40 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,513 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · derivative · entry 7 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,088 Underlying: Common Stock · 10,513 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 10,513 | $5.13 | $53,931.69 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 10,513 | $0.98 | $10,334.28 |
DisclosureSEC source: 0001209191-23-001980 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,133 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-22-060077 · doc4.xml · derivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,601 Underlying: Common Stock · 14,133 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 14,133 | $5.59 | $79,003.47 |
DisclosureSEC source: 0001209191-22-060077 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.35 to $5.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 14,133 | $1.08 | $15,263.64 |
DisclosureSEC source: 0001209191-22-060077 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-22-060077 · doc4.xml · derivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,734 Underlying: Common Stock · 15,000 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 15,000 | $6.02 | $90,300.00 |
DisclosureSEC source: 0001209191-22-060077 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 17:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 15,000 | $1.08 | $16,200.00 |
DisclosureSEC source: 0001209191-22-060077 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,266 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · derivative · entry 8 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,734 Underlying: Common Stock · 1,266 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,438 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · derivative · entry 7 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,438 shares Expires 2026-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,704 | $6.85 | $39,072.40 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · nonDerivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.72 to $6.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 1,266 | $1.08 | $1,367.28 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · price: This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 4,438 | $0.84 | $3,727.92 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 23,429 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · derivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 Underlying: Common Stock · 23,429 shares Expires 2026-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 23,429 | $6.94 | $162,597.26 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.80 to $7.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:53 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 23,429 | $0.84 | $19,680.36 |
DisclosureSEC source: 0001209191-22-055528 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 16:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,282 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-22-053456 · doc4.xml · derivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,867 Underlying: Common Stock · 4,282 shares Expires 2026-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 16:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 4,282 | $6.51 | $27,875.82 |
DisclosureSEC source: 0001209191-22-053456 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.40 to $6.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 16:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 4,282 | $0.84 | $3,596.88 |
DisclosureSEC source: 0001209191-22-053456 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 16:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,851 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-22-053456 · doc4.xml · derivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,149 Underlying: Common Stock · 24,851 shares Expires 2026-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 16:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 24,851 | $6.45 | $160,288.95 |
DisclosureSEC source: 0001209191-22-053456 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.31 to $6.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 16:09 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 24,851 | $0.84 | $20,874.84 |
DisclosureSEC source: 0001209191-22-053456 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 16:20 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 142,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-22-021474 · doc4.xml · derivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Stock · 142,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 25, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 31,163 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · derivative · entry 9 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 31,163 shares Expires 2026-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 31,163 | $12.08 | $376,449.04 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · nonDerivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 31,163 | $0.84 | $26,176.92 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · nonDerivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 51,352 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · derivative · entry 8 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,163 Underlying: Common Stock · 51,352 shares Expires 2026-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 51,352 | $12.16 | $624,440.32 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 51,352 | $0.84 | $43,135.68 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 42,590 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · derivative · entry 7 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,515 Underlying: Common Stock · 42,590 shares Expires 2026-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 42,590 | $12.66 | $539,189.40 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:10 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 42,590 | $0.84 | $35,775.60 |
DisclosureSEC source: 0001209191-21-064881 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 17:19 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050949 · doc4.xml · derivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.